



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Silver Spring MD 20993

September 23, 2020

Michelle Ryder
Lachman Consulting Services, Inc.
1600 Stewart Ave., Suite 604
Westbury, NY 11590

Sent via email to: m.ryder@lachmanconsultants.com

Dear Petitioner:

Your petition to the Commissioner of Food and Drug Administration requesting the FDA designate Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension/Drops, approved under ANDA 062488 as a new Reference Standard was received by this office on 09/23/2020 and it was assigned docket number FDA-2020-P-2004.

Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Dynna Bigby
Supervisory Administrative Proceedings Officer
Division of Dockets Management
FDA/Office of Operations (OO)